文献类型：期刊文献

英文题名：An oral NoV-rAd5 vaccine with built-in dsRNA adjuvant elicits systemic immune responses in mice

作者：Wang, Jindong[1,2];Ma, Yalin[2,3];Li, Jinsong[2];Peng, Rui[2];Mao, Tongyao[2];Sun, Xiaoman[2];Duan, Zhaojun[2]

第一作者：Wang, Jindong

通信作者：Duan, ZJ[1]

机构：[1]Weifang Med Univ, Dept Pathogen Biol, Weifang 261053, Peoples R China;[2]Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China;[3]Gansu Univ Tradit Chinese Med, Sch Publ Hlth, Lanzhou 730000, Peoples R China

第一机构：Weifang Med Univ, Dept Pathogen Biol, Weifang 261053, Peoples R China

通信机构：[1]corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China.

年份：2023

卷号：116

外文期刊名：INTERNATIONAL IMMUNOPHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85147874652);WOS:【SCI-EXPANDED(收录号:WOS:000944878500001)】；

基金：We thank Zhuozhuang Lu for providing us with the pKAd5ES-PmeI vector. We are very grateful to the technical assistance of Xiaohui Zou and Xiaojuan Guo. This work was supported by National Science and Technology Major Project of China (No.2018ZX10305409-004-002).

语种：英文

外文关键词：Human noroviruses; Recombinant adenoviruses; DsRNA; RIG-I; Vaccine

摘要：Norovirus (NoV) is an enteric pathogen notorious for causing epidemics of acute gastroenteritis. An effective vaccine against NoV is therefore urgently needed. A short double-stranded RNA (dsRNA) has been described that acts as a retinoic-acid-inducible gene-I agonist to induce the production of type I interferon; it also exhibits adjuvant activity. Using built-in dsRNA of different lengths (DS1 and DS2), we developed a recombinant adenovirus 5 (rAd5) expressing NoV VP1, and evaluated its immunogenicity following oral administration in a mouse model. An in vitro study demonstrated that the dsRNA adjuvants significantly enhanced VP1 protein expression in infected cells. The oral administration of both rAd5-VP1-DS vaccines elicited high serum levels of VP1-specific IgG and blocking antibodies, as well as strong and long-lasting mucosal immunity. There was no apparent difference in immunostimulatory effects in immunised mice between the two dsRNA adjuvants. This study indicates that an oral NoV-rAd5 vaccine with a built-in dsRNA adjuvant may be developed to prevent NoV infection in humans.